Loading…
Roivant Sciences Ltd. is projected to rise to $39.85 by 2027, a +35% move from its current price of $29.58. ROIV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.96 | $29.58 | $30.21 | -0.01% |
| May 30 | $28.71 | $29.58 | $30.47 | -0.01% |
| May 31 | $28.52 | $29.58 | $30.67 | -0.02% |
| Jun 1 | $28.36 | $29.57 | $30.85 | -0.02% |
| Jun 2 | $28.21 | $29.57 | $31.00 | -0.03% |
| Jun 3 | $28.09 | $29.57 | $31.14 | -0.03% |
| Jun 4 | $27.97 | $29.57 | $31.26 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $27.97 | $29.57 | $31.26 | -0.04% |
| Week 2 | $27.32 | $29.56 | $31.98 | -0.07% |
| Week 3 | $26.83 | $29.55 | $32.54 | -0.11% |
| Week 4 | $26.43 | $29.54 | $33.02 | -0.14% |
| Week 5 | $26.07 | $29.53 | $33.44 | -0.18% |
| Week 6 | $25.75 | $29.52 | $33.83 | -0.21% |
| Week 7 | $25.46 | $29.51 | $34.19 | -0.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Roivant Sciences Ltd. operates in the Healthcare sector and trades as ROIV. The stock is currently priced at $29.96 per share, with a market capitalization of $21.55B and a rank of 565 by market capitalization.
The near‑term price outlook shows a neutral start in 2026, with the forecasted 2026 average price of $29.96 and a 30-day range typically between $25.87 and $34.70. Over the full forecast horizon, the forecast envisions meaningful upside with bullish drift from 2027 onward, culminating in multi‑year highs in the 2030s and beyond.
A major floor 28.5% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 9.6% above — a clean break opens room to run.
A major ceiling 17.6% above — clearing it would confirm fresh momentum.
Key ROIV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ROIV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $30.50 | Sell | $29.86 | Sell |
| MA 10 | $29.73 | Sell | $29.70 | Sell |
| MA 20 | $29.09 | Buy | $29.33 | Buy |
| MA 50 | $28.51 | Buy | $28.49 | Buy |
| MA 100 | $26.91 | Buy | $26.67 | Buy |
| MA 200 | $22.14 | Buy | $23.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.55 | Neutral |
| Stoch RSI (14) | 24.79 | Neutral |
| CCI (20) | 40.34 | Neutral |
| Williams %R (14) | -67.38 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 3.57 | Buy |
| Bollinger %B (20,2) | 0.61 | Neutral |
| Stochastic %K (14) | 32.62 | Neutral |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 1.57 | Buy |
| Ultimate (7,14,28) | 52.22 | Neutral |
| Momentum (10) | 0.19 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 30.22 | Sell |
| ADX (14) | 11.84 | Neutral |
| ATR (14) | 0.68 | Info |
The 30‑day technical snapshot shows RSI(14) at 50, indicating neutral momentum. The 50‑day simple moving average sits at $28.45, above the 200‑day average of $21.96, signaling a constructive trend relative to longer-term support. Near-term support is at $27.41 and resistance at $32.41, with a 30‑day price range from $25.87 to $34.70.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.14 | $29.58 | $39.02 | 0% | Neutral | |
| $32.31 | $39.85 | $51.62 | +35% | Bullish | |
| $38.25 | $48.15 | $64.18 | +63% | Bullish | |
| $42.07 | $53.86 | $73.44 | +82% | Bullish | |
| $48.55 | $63.10 | $87.71 | +113% | Bullish | |
| $50.01 | $65.90 | $93.16 | +123% | Bullish | |
| $52.62 | $70.21 | $100.79 | +137% | Bullish | |
| $62.05 | $83.77 | $121.94 | +183% | Bullish | |
| $70.95 | $96.88 | $142.84 | +228% | Bullish | |
| $80.71 | $111.37 | $166.20 | +277% | Bullish | |
| $112.57 | $162.98 | $255.84 | +451% | Bullish | |
| $199.18 | $312.55 | $528.81 | +957% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $21.14 | $29.58 | $34.74 | +0.00% |
| June 2026 | $25.73 | $30.07 | $35.86 | +1.66% |
| July 2026 | $25.03 | $29.44 | $35.48 | -2.09% |
| August 2026 | $24.69 | $29.18 | $35.46 | -0.88% |
| September 2026 | $25.29 | $30.02 | $36.71 | +2.85% |
| October 2026 | $25.58 | $30.48 | $37.49 | +1.53% |
| November 2026 | $25.45 | $30.42 | $37.62 | -0.18% |
| December 2026 | $26.18 | $31.40 | $39.02 | +3.20% |
Click any year to see its month-by-month ROIV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ROIV to range from $21.14 to $39.02 through 2026. The $29.58 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ROIV price prediction for 2027 points to an average of $39.85 (low $32.31, high $51.62) — a potential gain of +35% on today's $29.58. Momentum favours further upside here.
In 2028, ROIV is projected to trade between $38.25 and $64.18, averaging $48.15 — a potential gain of +63% from today's $29.58. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Roivant Sciences Ltd.'s 2029 outlook centres on $53.86, within a $42.07 to $73.44 range. That is up +12% on the projected 2028 average. That marks a +82% change versus current levels. Momentum favours further upside here.
By 2030, ROIV could reach as high as $87.71, with a base case around $63.10 and support toward $48.55 — roughly +113% from $29.58. Buyers look set to stay in control over this stretch.
Expect ROIV to range from $50.01 to $93.16 through 2031. The $65.90 average target implies a +123% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The ROIV price prediction for 2032 points to an average of $70.21 (low $52.62, high $100.79) — a potential gain of +137% on today's $29.58. Buyers look set to stay in control over this stretch.
In 2033, ROIV is projected to trade between $62.05 and $121.94, averaging $83.77 — a potential gain of +183% from today's $29.58. That is up +19% on the projected 2032 average. Momentum favours further upside here.
Roivant Sciences Ltd.'s 2034 outlook centres on $96.88, within a $70.95 to $142.84 range. That is up +16% on the projected 2033 average. That marks a +228% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ROIV could reach as high as $166.20, with a base case around $111.37 and support toward $80.71 — roughly +277% from $29.58. Momentum favours further upside here.
Expect ROIV to range from $112.57 to $255.84 through 2040. The $162.98 average target implies a +451% move from current prices. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ROIV price prediction for 2050 points to an average of $312.55 (low $199.18, high $528.81) — a potential gain of +957% on today's $29.58. Momentum favours further upside here.
Investing $1,000 in ROIV today (≈ 33.806626 ROIV) could be worth
$10,566.24
+$9,566.24 (+957%) by 2050 · US Dollar
Based on the average projected ROIV price of $312.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ROIVwould be worth at today's price.
$1,000 invested in ROIV on May 27, 2025 (≈ 92.936801 ROIV) would be worth
$2,749.07
+$1,749.07 (+174.9%) today · 2.75× · US Dollar
Based on a ROIV entry price of $10.76 vs. today's $29.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $32.41 | $912.68 | -8.7% |
| 1 month ago | $27.85 | $1,062.12 | +6.2% |
| 3 months ago | $28.49 | $1,038.26 | +3.8% |
| 6 months ago | $20.81 | $1,421.43 | +42.1% |
| 1 year ago | $10.76 | $2,749.07 | +174.9% |
| All time (5.0y) ago | $9.86 | $3,000 | +200.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ROIV forecast.
Our base-case forecast reaches $59.00 around 2030.
Implied market cap at $59.00: $42.44B
The multi-year forecast points to a broad upside across the decade and into the 2030s. The 2026 forecast shows an average price of $29.96 with a neutral stance. By 2027 the average price is $40.63 and the max $52.99, with a 35.6% ROI and bullish sentiment.
In 2028 the average price is $49.19 and the max $66.09, with a 64.2% ROI and bullish sentiment, followed by 2029 with an average of $55.43 and a max of $76.25, an 85% ROI. The 2030 forecast shows an average of $64.69 and a max of $90.81, a 115.9% ROI and bullish sentiment, climbing further to 2031 (avg $67.50, max $96.44, ROI 125.3%), 2032 (avg $72.37, max $105.07, ROI 141.6%), and 2033 (avg $86.49, max $127.41, ROI 188.7%). The long-range view extends to 2034–2035 with higher averages and ROIs, and to 2040 (avg $168.83, ROI 463.5%) and 2050 (avg $327.03, ROI 991.6%).
These figures illustrate substantial upside potential but are estimates, not guarantees.
Tap a question to reveal the answer.
2030 Avg $64.69, min $49.39, max $90.81, ROI 115.9%, sentiment BULLISH.
Forecasts show bullish sentiment in 2027–2050 with rising average prices (e.g., 2027 Avg $40.63, 2030 Avg $64.69, 2040 Avg $168.83, 2050 Avg $327.03) and high ROIs, but 2026 is neutral. These are estimates, not guarantees.
Yes. The forecast's max prices exceed $100 in several years: 2032 max $105.07, 2033 max $127.41, with 2030 max $90.81. Reaching or exceeding $100 appears possible in the early 2030s based on the provided forecast.
Current price is $29.96 and market capitalization is $21.55B.
RSI(14) is 50, SMA(50) is $28.45, SMA(200) is $21.96. Key levels are support at $27.41 and resistance at $32.41, with a 30-day price range of $25.87 to $34.70.
Roivant Sciences Ltd. Community Discussion
0Share your Roivant Sciences Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.